Background: Long noncoding RNAs (lncRNAs) are a novel type of endogenous noncoding RNA that are involved in the regulation of gene expression and play important roles in several types of cancer. LncRNA001089 is an intergenic lncRNA associated with cancer progression and tumor occurrence; however, the role and function of LncRNA001089 in glioma remains unclear.
Methods: In this study, we determined the expression levels of LncRNA001089 in tissues of glioma patients and explored its effect on glioma cell metastasis and proliferation using U251 glioma cell lines. Quantitative real-time PCR (qRT-PCR) technology was used to verify the expression levels of LncRNA001089 in the 127 tissues of glioma patients. Functional studies of LncRNA001089 were performed in glioma cells, including a colony formation assay, evaluation of proliferation by CCK-8, evaluation of apoptosis by flow cytometry, and evaluation of migration and invasion in vitro by Transwell assays. Tumorigenesis was evaluated in vivo in nude mice.
Results: LncRNA001089 was downregulated in glioma tissues, evaluated by qRT-PCR. Kaplan-Meier analysis indicated that the downregulation of LncRNA001089 expression was associated with poor prognoses in glioma patients. Multivariate analysis demonstrated that LncRNA001089 downregulation and WHO high-grade glioma were independent factors that both predicted poor outcomes for glioma patients. Cells with LncRNA001089 stable overexpression exhibited decreased capacities for proliferation, migration, and invasion in vitro, and restrained nude mouse tumorigenesis in vivo, but LncRNA001089 overexpression enhanced apoptosis.
Conclusions: Our data suggest that LncRNA001089 plays a critical role in the development of glioma and may function as a potential novel biomarker and/or a therapeutic target for treatment of glioma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2018.180817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma.
Nat Commun
December 2024
Cancer Center, Department of Neurosurgery, Zhejiang Provincial People's Hospital，Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Approximately 90% of glioblastoma recurrences occur in the peritumoral brain zone (PBZ), while the spatial heterogeneity of the PBZ is not well studied. In this study, two PBZ tissues and one tumor tissue sample are obtained from each patient via preoperative imaging. We assess the microenvironment and the characteristics of infiltrating immune/tumor cells using various techniques.
View Article and Find Full Text PDFNeoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.
Nat Commun
December 2024
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Glioblastoma is immunologically "cold" and resistant to single-agent immune-checkpoint inhibitors (ICI). Our previous study of neoadjuvant pembrolizumab in surgically-accessible recurrent glioblastoma identified a molecular signature of response to ICI and suggested that neoadjuvant pembrolizumab may improve survival. To increase the power of this observation, we enrolled an additional 25 patients with a primary endpoint of evaluating the cell cycle gene signature associated with neoadjuvant pembrolizumab and performed bulk-RNA seq on resected tumor tissue (NCT02852655).
View Article and Find Full Text PDFA sample size analysis of a mathematical model of longitudinal tumor volume and progression-free survival for Bayesian individual dynamic predictions in recurrent high-grade glioma.
CPT Pharmacometrics Syst Pharmacol
December 2024
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Patients with recurrent high-grade glioma (rHGG) have a poor prognosis with median progression-free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow-up imaging studies to adaptively predict the risk of progression.
View Article and Find Full Text PDFRadiological features of basal ganglia germinoma: a case report and early-stage alerts.
Front Oncol
December 2024
Diagnostic Imaging Center, Tam Anh General Hospital, Ho Chi Minh City, Vietnam.
Basal ganglia germinomas are uncommon neoplasms. Basal ganglia germinomas exhibit high sensitivity to both radiation therapy and chemotherapy. In contrast, surgery is the standard treatment for most primary brain tumors (such as gliomas, which are the most common tumors in the pediatric basal ganglia region).
View Article and Find Full Text PDFEvaluation of early metabolic changes following vorasidenib using FET PET in patients with -mutant gliomas.
Neurooncol Adv
November 2024
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase () inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI showed limited response, with only 11% of patients having objective responses. Studies suggest that serial PET imaging with radiolabeled amino acids, such as -(2-[ F]-fluoroethyl)-L-tyrosine (FET) PET, may provide earlier and more informative assessments of treatment response than MRI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!